Risk assessment of over-the-counter cannabinoid-based cosmetics: Legal and regulatory issues governing the safety of cannabinoid-based cosmetics in the UAE
Posted on July 12, 2021 By LabLynx Journal articles
Contents
Tools
Actions
General
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Cite this page
- Get shortened URL
- Download QR code
- Wikidata item
Print/export
- Download as PDF
- Printable version
Chemical compound
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C14H19N |
Molar mass | 201.313 g·mol−1 |
3D model (JSmol) | |
| |
|
Camfetamine (N-methyl-3-phenyl-norbornan-2-amine) is a stimulant drug closely related to the appetite suppressant fencamfamine, being its N-methyl homologue.[1] It has been sold as a designer drug following the banning of mephedrone and related substituted cathinone derivatives in many countries,[2] and reportedly has slightly stronger stimulant effects than fencamfamine, but with correspondingly more severe side effects.
See also
References
- ^ DE patent 1110159, Thesing J, Seitz G, Hotovy R, Sommer S, "Verfahren zur Herstellung analeptisch wirksamer N-substituierter Aminonorcamphanderivate bzw. von deren Säureadditionssalzen und quaternären Ammoniumverbindungen", issued 1961-07-06, assigned to E. Merck AG
- ^ Kavanagh P, Angelov D, O'Brien J, Power JD, McDermott SD, Talbot B, et al. (April 2013). "The synthesis and characterization N-methyl-3-phenyl-norbornan-2-amine (Camfetamine™)". Drug Testing and Analysis. 5 (4): 247–53. doi:10.1002/dta.411. PMID 22374810.
D1-like |
| ||||||
---|---|---|---|---|---|---|---|
D2-like |
| ||||||
by LabLynx